AACR 2024 | Emerging combinatory immunotherapies show promise for mCRPC

Hannah McManus, MD, Duke Cancer Institute, Duke University School of Medicine, Durham, NC, provides a promising summary of the use of combination immunotherapies for the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC). The homologous recombination repair (HRR) pathway is a frequently mutated pathway in advanced prostate cancer, and excellent clinical outcomes have been observed in patients with mCRPC and mutated HRR genes treated with a combination of androgen receptor signaling inhibitors (ARSI) and Poly-ADP ribose polymerase (PARP) inhibitors. These results signal the importance of employing early molecular testing, to plan targeted immunotherapeutic treatments. This interview took place at the 2024 American Association for Cancer Research (AACR) in San Diego, CA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.